Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Lonza adds gene-editing service with CRISPR license
by Rick Mullin
January 7, 2019
| A version of this story appeared in
Volume 97, Issue 1
Lonza has licensed CRISPR-Cas9 gene-editing technology from ERS Genomics for use in its new cell biology research division. The drug services firm is adding gene editing to improve the development of cell lines, according to Sarah Holland, head of licensing for Lonza’s biologics business. “If you are going to create and improve cell lines, you really need effective modern tools, and one of those is CRISPR-Cas9,” Holland says. The new research section plans to license another gene-editing technology in 2019, she says.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter